CYC interesting, continued growth in rev for it's IP in ROW and going live in US after FDA approval of IP in September.
Liquidity not high so maybe more an STT op.
Metrics high but very low in comparison to other emerging biotech's, and this company has been supplying mature markets in Europe with it's IP for years.
